Dimebon

Description	Latrepirdine (INN, also known as dimebolin and sold as Dimebon), is an antihistamine drug. Research is continuing in both Russia and western nations into potential applications as a neuroprotective drug to combat Alzheimer’s disease and, possibly, as a nootropic as well. However, a Phase III clinical trial for Alzheimer’s disease treatment failed to show any benefit. Latrepirdine operates through multiple mechanisms of action, blocking the action of neurotoxic beta-amyloid proteins, inhibiting L-type calcium channels, modulating the action of AMPA and NMDA glutamate receptors, exerting a neuroprotective effect by blocking a novel target that involves mitochondrial pores, blocking a number of other receptors including α-adrenergic, 5-HT2C, 5-HT5A, and 5-HT6.
Pathways	Neuro Signaling Pathway GPCR/G Protein
Targets	5 HT Receptor/Serotonin Receptor Adrenergic Receptor Histamine Receptor

Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.

For product details of different batches, please contact our Customer

Products are for research use only and not for human use. We do not sell to patients.